Clinical trials: PD - Parkinson's Disease
Parkinson Disease
Parkinson's Research: The Organized Genetics Initiative
The purpose of this trial is to study genetic and other risk factors that may be important in the development of Parkinson's disease.
- Trial name
- PROGENI (NCT00086073)
- Where
- 58 sites in United States, Canada and 1 more
- Volunteers
- 1,800 people
- Sponsor
- Indiana University
Parkinson Disease (PD)
Changes in Movement, Fitness, and Quality of Life in People With Parkinson's Disease After Different Exercise Programs
Parkinson's disease (PD) is a progressive neurological condition that can affect movement, balance, endurance, and overall quality of life.
- Trial name
- NCT07221266
- Testing
- Guided Cycling, Non-Contact Boxing, Traditional Physical Therapy Program (Standard of Care)
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- University of Texas, El Paso
Parkinson's Disease
Safinamide in Levodopa Induced Dyskinesia in Parkinson's Disease Subjects
Approximately twenty four (24) subjects will participate in this research trial. The research trial will be conducted in approximately twelve (12) medical centers in the following countries: Germany, France, South Africa, Austria…
- Trial name
- Safinamide-LID (NCT01113320)
- Testing
- Safinamide
- Where
- 11 sites in Austria, Canada and 3 more
- Volunteers
- 26 people
- Sponsor
- Newron Pharmaceuticals SPA
Parkinsons Disease (PD)
Edmond J. Safra Accelerating Clinical Trials in Parkinson's Disease: A Multiarm Multi-stage Platform Trial
Parkinson's disease (PD) is currently the fastest-growing neurological condition globally. It is projected to affect 172,000 people in the UK by 2030,with the current annual cost to the country being ~£3.6 billion.
- Trial name
- EJS ACT-PD (NCT07207057)
- Testing
- Telmisartan, Terazosin (Hytrin)
- Where
- 2 sites in United Kingdom
- Volunteers
- 1,200 people
- Sponsor
- University College, London
Parkinson Disease
Special Survey on Parkinson's Disease (PD) Patients Without Concomitant Use of L-Dopa
The survey is conducted to collect safety and effectiveness information in Parkinson's Disease patients treated with Pramipexole without concomitant L-Dopa supplementation in the daily clinical settings in Japan.
- Trial name
- NCT00613301
- Where
- 119 sites in Japan
- Volunteers
- 416 people
- Sponsor
- Boehringer Ingelheim
Parkinson's Disease
A Randomised Controlled Trial (RCT) to Evaluate Use of an Individual Auditory Cueing Device's (IACD's) on Freezing and Gait in People With Parkinson's Disease (PD)
The primary aim of the study is to evaluate the effect of an IACD i.e. Apple iPod-shuffle, on freezing and gait speed in people with a diagnosis of PD through the implementation of a randomised controlled trial.
- Trial name
- NCT00727467
- Testing
- Auditory Cueing Device
- Where
- 3 sites in Ireland
- Volunteers
- 47 people
- Sponsor
- University of Dublin, Trinity College
Excessive Daytime Sleepiness, Parkinson's Disease
Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients
The objective of this trial is to define the minimum effective dose of BF 2.649 between 5 mg, 10 mg, 20 mg or 40 mg versus placebo in reducing the Excessive Daytime Sleepiness of Parkinson's disease patients
- Trial name
- NCT00642928
- Testing
- BF 2.649 5 mg, BF 2.649 10 mg, BF 2.649 20 mg
- Where
- France
- Volunteers
- 108 people
- Sponsor
- Bioprojet
Deep Brain Stimulation, Parkinson's Disease and Parkinsonism
Neural Mechanisms and Clinical Applications of DBS for Modulating Sleep Dysregulation in PD
Parkinson's disease (PD) is a prevalent neurodegenerative disorder characterized by both motor and non-motor symptoms. Subthalamic nucleus (STN) deep brain stimulation (DBS) effectively alleviates motor symptoms; however…
- Conditions
- Deep Brain Stimulation, Parkinson's Disease and Parkinsonism, Sleep Disorder
- Trial name
- NCT06914466
- Testing
- Deep Brain Stimulation
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Xuanwu Hospital, Beijing
Parkinson's Disease (PD)
Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide
The purpose of this study is to determine the effect of three single oral doses of nebicapone (50 mg, 100 mg and 200 mg) on the levodopa pharmacokinetics when administered in combination with a single-dose of controlled release…
- Trial name
- NCT02778594
- Testing
- BIA 3-202, levodopa 100 mg / benserazide 25 mg
- Where
- Portugal
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Bial - Portela C S.A.
Parkinson Disease, Apathy
Move to Improve Physical Activity in Parkinson's Disease
Apathy is a multi-dimensional behavior characterized by impairments to motivation, planning and initiation; collectively called, goal-directed behavior.
- Trial name
- MoTIvatE (NCT04051151)
- Testing
- Gameficiation
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- University of Pennsylvania
Parkinson's Disease, Levodopa Induced Dyskinesia (LID)
Efficacy and Safety of JM-010 in PD With Levodopa-Induced Dyskinesia
The purpose of a randomized, double-blind, placebo-controlled, 2-way crossover study is to evaluate the efficacy, safety/tolerability and pharmacokinetics of JM-010 for the treatment of subjects with Parkinson's Disease (PD) with…
- Trial name
- LID (NCT02439203)
- Testing
- JM-010
- Where
- South Africa
- Volunteers
- 30 people
- Sponsor
- Bukwang Pharmaceutical
Parkinson's Disease
A Study to Evaluate the Safety, Tolerability, PK and PD of HNC364 Injectable Suspension
This is a non-randomized, dose-escalation first-in-human study to evaluate the safety, tolerability, PK, and PD of HNC364 following intramuscular administration of single ascending doses.
- Trial name
- NCT05523570
- Testing
- HNC364
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Guangzhou Henovcom Bioscience Co. Ltd.
Parkinson Disease(PD)
Rhythm Psychophysics With Parkinson's Patients
The goal of this interventional study is to understand how the rhythmic abilities of individuals in the early stages of Parkinson's Disease (PD) are impacted by their levels of dopamine.
- Trial name
- RPPD (NCT07647913)
- Testing
- Withholding Levodopa
- Where
- Canada
- Volunteers
- 34 people
- Sponsor
- McMaster University
Idiopathic Parkinson´s Disease
Safety, Tolerability and Symptomatic Efficacy of the ROCK-Inhibitor Fasudil in Patients With Parkinson's Disease
The aim of this phase Ila trial is to provide evidence on safety, tolerability and symptomatic efficacy of the ROCK-inhibitor Fasudil in patients with early Parkinson's disease (PD).
- Trial name
- NCT05931575
- Testing
- Fasudil hydrochloride
- Where
- Germany
- Volunteers
- 81 people
- Sponsor
- Technical University of Munich
Parkinson Disease, Dyspepsia
Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms
The purpose of this study is to determine whether DA-9701(Motilitone) is effective and safe for the treatment on health-related quality of life in Parkinson's disease (PD) patients with gastrointestinal symptoms.
- Trial name
- PASS-GI (NCT02775591)
- Testing
- DA-9701
- Where
- 5 sites in South Korea
- Volunteers
- 147 people
- Sponsor
- Seoul National University Hospital
Parkinson's Disease (PD), Anxiety
Blood Flow Restriction Aerobic Exercise for Balance and Anxiety in Parkinson's Disease
Reducing balance problems and anxiety severity are the top two research uncertainties for people with Parkinson's disease (PD). Besides having a mutually aggravating relationship between postural impairment and anxiety severity…
- Conditions
- Parkinson's Disease (PD), Anxiety, Postural Balance
- Trial name
- NCT07831980
- Testing
- Aerobic Exercise with Blood Flow Restriction, Aerobic Exercise without Blood Flow Restriction
- Volunteers
- 54 people
- Sponsor
- National Cheng-Kung University Hospital
Parkinson's Disease (PD), Healthy Aging
Exoskeleton-Assisted Mobility in Aging and in Parkinson's Disease
This study will evaluate whether a wearable robotic exoskeleton can improve mobility, balance, and walking in healthy older adults and in individuals living with Parkinson's disease, populations at high risk of falls and mobility…
- Trial name
- NCT07567482
- Testing
- Exoskeleton
- Where
- Canada
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Centre intégré de santé et de services sociaux de l'Outaouais
Idiopathic Parkinson's Disease (PD)
Study on the Incidence of Malignant Neoplasms in Patients With Parkinson's Disease and Heterozygous Mutation of the GBA Gene
This multicenter retrospective observational study investigates the incidence of malignant neoplasms in Parkinson's disease (PD) patients carrying heterozygous pathogenic variants in the GBA1 gene.
- Trial name
- ONCOGBA (NCT06814431)
- Where
- 4 sites in Italy
- Volunteers
- 3,000 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Parkinson's Disease
A Non-Blinded Study Demonstrating the Effectiveness and Safety of Azilect Alone or in Combination Therapy in Parkinson's Disease
Patients with Parkinson's Disease (PD) will be divided into 2 groups at each study center at their first visit based on the drugs they are taking for their PD: Group 1 Patients using Azilect and no other therapy.
- Trial name
- NCT00399477
- Testing
- rasagiline mesylate, Rasagiline mesylate plus Mirapex, Rasagiline mesylate with Levodopa
- Volunteers
- 200 people
- Sponsor
- Teva Neuroscience, Inc.
Parkinson's Disease
Study Assessing Tolerability and Safety and Exploring the Immunogenicity and Therapeutic Activity of AFFITOPE® PD01A in PD-GBA Patients
This is a randomized, placebo-controlled, parallel group, patient-blind, single-center phase I clinical trial of repeated once every 4 weeks administration by subcutaneous injection of AFFITOPE® PD01A, adsorbed to aluminium oxide…
- Trial name
- NCT02758730
- Testing
- AFFITOPE® PD01A + Adjuvant, Adjuvant without active component
- Where
- Germany
- Sponsor
- Affiris AG